Drug reps pitching you Nefecon? Catch-up with the RCT in our #TenTweetNephJC tweetorial

#TenTweetNephJC returns in 2023! Catch-up rapidly with the biggest trials in nephrology.

Up first is NefIgArd.

We all say we hate steroids, but really we love their efficacy but hate their side-effects, right?

IgA nephropathy is again the subject of a steroid trial🧵 pic.twitter.com/sh0xtKPhsP
— Nephrology Journal Club (@NephJC) January 20, 2023